The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical trials have shown the therapeutic ...

2024年4月，该药物获得美国 ...

今日（3月13日），中国国家药监局药品审评中心（CDE）官网最新公示， Seagen公司和再鼎医药共同申报的 注射用维替索妥尤单抗 的上市申请获得受理。 根据再鼎医药新闻稿， 维替索妥尤单抗（tisotumab vedotin）是一种 靶向TF的抗体偶联药物（ADC） 。 该产品申报上市的适应症为： 用于治疗系统性治疗期间或之后病情进展的复发或转移性宫颈癌患者。

3月10日，中国国家药监局药品审评中心(CDE)官网最新公示，辉瑞(PFE.US)公司旗下Seagen申报的1类新药PF-08046054(注射用冻干粉针)获得临床试验默示许可 ...

Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States Koch Institute for Integrative Cancer Research, Massachusetts Institute of ...

The poster, “Characterization of Antigen-Agnostic Tumor-Selective Delivery and Immunomodulatory Activities of Auristatin and Maytansinoid alphalex™ Peptide-Drug Conjugates,” highlighted preclinical ...

1St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria. 2Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.

ADC药物 cIRCR201-dPBD IRCR201抗体-连接子-细胞毒性药物吡咯并苯并二氮杂䓬（dPBD） ADC药物 XMT-1522 人源化lgG1单克隆抗体HT-19-连接子-微管蛋白抑制剂AF-HPA ADC药物 ZW49 抗体ZW25-连接子-N-酰基磺酰胺auristatin ADC药物 德曲妥珠单抗（DS-8201T-DXd）Enhertu ADC药物 迪西妥单抗-连接 ...